Radiotherapy is one of the cornerstones of cancer treatment, being a component of management in at least half of all cancer patients. Increasingly, radiotherapy is used in multimodal treatment protocols in combination with surgery and chemotherapy. The best outcomes are achieved when specialists in each of these disciplines work in a multidisciplinary way, understanding the benefits and limitations that each brings to the patient's management. The aim is to individualise treatment using the best evidence available while continually advancing our knowledge through clinical trials. The Trans-Tasman Radiation Oncology Group has taken a leadership role in this regard.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 Division of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, VIC.
- 2 Division of Oncology, Royal Brisbane Hospital, Brisbane, QLD.
- 1. Kalff V, Hicks R, MacManus MP, et al. The clinical impact of F-18 FDG positron emission tomographic scanning in patients with lung cancer: a prospective study. J Clin Oncol 2000; 19: 111-118.
- 2. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000; 18: 3904-3911.
- 3. National Strategic Plan for Radiation Oncology, 2001. The Tripartite Committee, The Royal Australian and New Zealand College of Radiologists. Available at <http://www.ranzcr.edu.au/>.
- 4. Tobias JS, Ball DL. Synchronous chemoradiation for squamous cell carcinomas [editorial]. BMJ 2001; 322: 876-878.
- 5. Brahme A. Individualizing cancer treatment: biological optimization models in treatment planning and delivery. Int J Radiat Oncol Biol Phys 2001; 49: 327-337.